Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 15/20 | 0.79 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17028620 | 0.88 | FFAR4 (1.00) | FFAR4FFAR1AKR1B1 | |
| SCHEMBL17028633 | 0.81 | FFAR4 (0.73) | FFAR4FFAR1 | |
| SCHEMBL17028725 | 0.80 | FFAR4 (0.79) | FFAR4FFAR1 | |
| SCHEMBL17028635 | 0.78 | FFAR4 (0.68) | FFAR4FFAR1 | |
| SCHEMBL17028617 | 0.74 | FFAR4 (0.80) | FFAR4FFAR1 | |
| SCHEMBL17028682 | 0.71 | FFAR4 (0.81) | FFAR4FFAR1 | |
| SCHEMBL17460606 | 0.71 | FFAR4 (0.76) | FFAR4 | |
| SCHEMBL17028577 | 0.71 | FFAR4 (0.84) | FFAR4FFAR1 | |
| SCHEMBL29268072 | 0.69 | CYP4Z1 (0.44) | FFAR4CYP4F2CYP4A11 | |
| SCHEMBL17028529 | 0.68 | FFAR4 (1.00) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107901-B1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | PIRAMAL ENTPR LTD (IN) | 2020-04-01 | — | — | EP | disclosed |
| US-10227360-B2 | Compounds for use as GPR120 agonists | Piramal Enterprises Limited (IN) | 2019-03-12 | — | — | US | disclosed |
| EP-3107901-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2016-12-28 | — | — | EP | disclosed |
| US-20160347768-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2016-12-01 | — | — | US | disclosed |
| WO-2015125085-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227360-B2 | Compounds for use as GPR120 agonists | GPR119, GPR55, GPR180 | FFAR4 26/4885FFAR1 11/4885CYP4F2 545/4885 |
| US-20160347768-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | GPR119, GPR55, GPR180 | FFAR4 26/4885FFAR1 11/4885CYP4F2 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.